Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.6
4.9
Journals
Marine Drugs
Special Issues
Products from Marine Actinomycetes
share announcement

Products from Marine Actinomycetes

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (3 July 2020) | Viewed by 14230

Special Issue Editor

Dr. Olga Genilloud

E-Mail Website
Guest Editor
Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Parque Tecnológico Ciencias de la Salud, Avenida del Conocimiento 34, Granada, Spain
Interests: natural products; drug discovery; antibiotics; antimicrobial resistance; natural product biosynthesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The marine environment is one of the most intensively explored sources of microbial diversity and in recent years new taxonomic groups of marine actinomycetes have been described with extraordinary rich metabolic capacities. Marine-obligate and marine-derived species are one of richest sources of structurally diverse secondary metabolites. The metabolic diversity within marine actinobacteria is supported by the exponentially growing genome sequence information available from public databases. The evidence of a broad distribution of indigenous actinomycetes in the marine environment is now overwhelming as well as the presence of novel strains that have not yet been cultivated from these microbial communities.

Current technology advances and available omics platforms supporting the development of merging disciplines in synthetic biology, chemistry and microbiology are driving the exploration of the broad microbial and chemical diversities in the marine environment. All together they are paving the way to enable the discovery of novel families of bioactive compounds with potential applications in a broad range of therapeutic and biotechnology areas.

This special issue aims to cover all most recent advances in the field of marine actinomycetes natural products research and how these approaches are contributing to define novel trends in marine natural products drug discovery.

Dr. Olga Genilloud
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Marine natural products
  • Marine actinomycetes
  • Metabolomics
  • Genome-based discovery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 3280 KiB  
Article
Identification, Cloning and Heterologous Expression of the Gene Cluster Directing RES-701-3, -4 Lasso Peptides Biosynthesis from a Marine Streptomyces Strain
by Daniel Oves-Costales, Marina Sánchez-Hidalgo, Jesús Martín and Olga Genilloud
Mar. Drugs 2020, 18(5), 238; https://doi.org/10.3390/md18050238 - 1 May 2020
Cited by 12 | Viewed by 3713
Abstract
RES-701-3 and RES-701-4 are two class II lasso peptides originally identified in the fermentation broth of Streptomyces sp. RE-896, which have been described as selective endothelin type B receptor antagonists. These two lasso peptides only differ in the identity of the C-terminal residue [...] Read more.
RES-701-3 and RES-701-4 are two class II lasso peptides originally identified in the fermentation broth of Streptomyces sp. RE-896, which have been described as selective endothelin type B receptor antagonists. These two lasso peptides only differ in the identity of the C-terminal residue (tryptophan in RES-701-3, 7-hydroxy-tryptophan in RES-701-4), thus raising an intriguing question about the mechanism behind the modification of the tryptophan residue. In this study, we describe the identification of their biosynthetic gene cluster through the genome mining of the marine actinomycete Streptomyces caniferus CA-271066, its cloning and heterologous expression, and show that the seven open reading frames (ORFs) encoded within the gene cluster are sufficient for the biosynthesis of both lasso peptides. We propose that ResE, a protein lacking known putatively conserved domains, is likely to play a key role in the post-translational modification of the C-terminal tryptophan of RES-701-3 that affords RES-701-4. A BLASTP search with the ResE amino acid sequence shows the presence of homologues of this protein in the genomes of eight other Streptomyces strains, which also harbour the genes encoding the RES-701-3, -4 precursor peptide, split-B proteins and ATP-dependent lactam synthetase required for the biosynthesis of these compounds. Full article
(This article belongs to the Special Issue Products from Marine Actinomycetes)
►▼ Show Figures

Figure 1

13 pages, 1918 KiB  
Article
Shellmycin A–D, Novel Bioactive Tetrahydroanthra-γ-Pyrone Antibiotics from Marine Streptomyces sp. Shell-016
by Yong Han, Yan Wang, Yuehan Yang and Haotong Chen
Mar. Drugs 2020, 18(1), 58; https://doi.org/10.3390/md18010058 - 16 Jan 2020
Cited by 13 | Viewed by 4865
Abstract
Four novel bioactive tetrahydroanthra-γ-pyrone compounds, shellmycin A–D (1–4), were isolated from the marine Streptomyces sp. shell-016 derived from a shell sediment sample collected from Binzhou Shell Dike Island and Wetland National Nature Reserve, China. The structures of these four [...] Read more.
Four novel bioactive tetrahydroanthra-γ-pyrone compounds, shellmycin A–D (1–4), were isolated from the marine Streptomyces sp. shell-016 derived from a shell sediment sample collected from Binzhou Shell Dike Island and Wetland National Nature Reserve, China. The structures of these four compounds were established by interpretation of 1D and 2D NMR and HR-MS data, in which the absolute configuration of 1 was confirmed by single crystal X-ray diffraction, and compound 3 and 4 are a pair of stereoisomers. Compound 1–4 exhibited cytotoxic activity against five cancer cell lines with the IC50 value from 0.69 μM to 26.3 μM. Based on their structure–activity relationship, the putative biosynthetic pathways of these four compounds were also discussed. Full article
(This article belongs to the Special Issue Products from Marine Actinomycetes)
►▼ Show Figures

Graphical abstract

19 pages, 2024 KiB  
Article
New Napyradiomycin Analogues from Streptomyces sp. Strain CA-271078
by Daniel Carretero-Molina, Francisco Javier Ortiz-López, Jesús Martín, Daniel Oves-Costales, Caridad Díaz, Mercedes de la Cruz, Bastien Cautain, Francisca Vicente, Olga Genilloud and Fernando Reyes
Mar. Drugs 2020, 18(1), 22; https://doi.org/10.3390/md18010022 - 26 Dec 2019
Cited by 21 | Viewed by 5111
Abstract
As part of our continuing efforts to discover new bioactive compounds from microbial sources, a reinvestigation of extracts of scaled-up cultures of the marine-derived Streptomyces sp. strain CA-271078 resulted in the isolation and structural elucidation of four new napyradiomycins (1–3 [...] Read more.
As part of our continuing efforts to discover new bioactive compounds from microbial sources, a reinvestigation of extracts of scaled-up cultures of the marine-derived Streptomyces sp. strain CA-271078 resulted in the isolation and structural elucidation of four new napyradiomycins (1–3, 5). The known napyradiomycin SC (4), whose structural details had not been previously described in detail, and another ten related known compounds (6–15). The structures of the new napyradiomycins were characterized by HRMS and 1D- and 2D-NMR spectroscopies and their relative configurations were established through a combination of molecular modelling with nOe and coupling constants NMR analysis. The absolute configuration of each compound is also proposed based on biosynthetic arguments and the comparison of specific rotation data with those of related compounds. Among the new compounds, 1 was determined to be the first non-halogenated member of napyradiomycin A series containing a functionalized prenyl side chain, while 2–4 harbor in their structures the characteristic chloro-cyclohexane ring of the napyradiomycin B series. Remarkably, compound 5 displays an unprecedented 14-membered cyclic ether ring between the prenyl side chain and the chromophore, thus representing the first member of a new class of napyradiomycins that we have designated as napyradiomycin D1. Anti-infective and cytotoxic properties for all isolated compounds were evaluated against a set of pathogenic microorganisms and the HepG2 cell line, respectively. Among the new compounds, napyradiomycin D1 exhibited significant growth-inhibitory activity against methicillin-resistant Staphylococcus aureus, Mycobacterium tuberculosis, and HepG2. Full article
(This article belongs to the Special Issue Products from Marine Actinomycetes)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop